The HercepTestTM is an immunohistochemical test used to determine whether a tumour overexpresses human epidermal growth factor receptor 2 (HER2) protein, which occurs in approximately 20% to 30% of breast cancer cases and is associated with poorer prognosis [58, 59]. The gene discussed is ERBB2; the disease is neoplasm.